Vaccination rates have risen steadily in recent weeks as fears of the Delta variant have increased. Providers delivered about 837,000 rounds a day late last week, and Mr Biden said the most recent seven-day total was the highest since early July. He said more people in Alabama, Arkansas, Louisiana and Mississippi — some of the states with the highest caseloads — received their first injections in the past month than in the previous two months combined.
dr. Marks said myths about the vaccines remain a major barrier to fighting the pandemic, including false claims that injections would cause infertility, promote rather than prevent Covid-19, and even led to thousands of deaths.
“Let me be clear: these claims are simply not true,” he said.
The FDA is in the midst of a blizzard of decisions about coronavirus vaccines. The next major thing that comes up is whether booster shots should be allowed.
The Biden administration said last week it planned to offer third injections to adults who received the Pfizer and Moderna vaccines eight months after their second injection, starting Sept. 20. Third injections are already allowed for some people with immune deficiencies, but the risk benefit calculation is different for the general population.
Federal health officials said both Pfizer’s and Moderna’s vaccines, which rely on similar technology, are declining in strength over time. That trend, they said, has coincided with the rise of the particularly dangerous Delta variant, leaving those who completed their vaccinations at the beginning of the year increasingly vulnerable to infection.
Some public health experts have challenged the booster shot plan as premature. They say the available data shows that the vaccines hold up well against serious illnesses and hospitalizations, including the Delta variant. Additional injections would only be justified if the vaccines didn’t meet that standard, some said.
Regulators are still reviewing Moderna’s application for full approval of its vaccine, which it filed in June, a month after Pfizer. That decision could take several weeks. Johnson & Johnson is expected to apply for full approval soon.
Susan C. Beachy and Coral Murphy Marcos reporting contributed.